Fruquintinib plus chemo versus bevacizumab plus chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of advanced colorectal cancer that has spread.
- You must have already tried at least two standard chemotherapy regimens, including drugs like fluoropyrimidine, oxaliplatin, and irinotecan.
- You need to have had bevacizumab (Avastin) before in your treatment.
- You should be generally active and able to care for yourself (ECOG score 0 or 1).
- You should not have taken certain other targeted therapies like TAS-102 or drugs such as anlotinib or apatinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.